Etrinabdione

N/A

Report date: 2025/01/16 15:10:31
NME

Base Information

Drug NameEtrinabdione
Drug Alias NameEtribnabdioneVCE-004EHP-101VCE-004.8
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCannabinoid CB2 receptor agonistsPeroxisome proliferator-activated receptor γ antagonists
TargetsPeroxisome proliferator-activated receptor γCannabinoid CB2 receptor
Therapy Area/IndicationsScleroderma, DiffusePeripheral Arterial DiseaseMultiple Sclerosis, Relapsing-Remitting
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto RicoNew Zealand +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesVivacell BiotechnologyEmerald
China Registration ClassN/A

Develop Information

Active CompaniesVivaCell Biotechnology España SL
Inactive CompaniesEmerald Health Pharmaceuticals Inc
Active IndicationsPeripheral Arterial Disease
Inactive IndicationsScleroderma, DiffuseMultiple Sclerosis, Relapsing-Remitting

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank